PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
1.820
-0.090 (-4.71%)
At close: Nov 3, 2026, 4:00 PM EST
1.900
+0.080 (4.40%)
Pre-market: Nov 4, 2026, 8:16 AM EST
PAVmed Revenue
PAVmed had revenue of $33.00K in the quarter ending June 30, 2026, with 450.00% growth. This brings the company's total for the last twelve months to $112.00K, down -89.02% year-over-year. In the year 2025, PAVmed had annual revenue of $71.00K, down -97.63%. That makes PAVmed the 45,975th largest company in the world by revenue and 6,763rd in the United States.
Revenue (ttm)
$112.00K
Revenue Growth
-89.02%
P/S Ratio
113.63
Revenue / Employee
$2,732
Employees
41
Market Cap
12.73M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 71.00K | -2.92M | -97.63% |
| Dec 31, 2024 | 3.00M | 543.00K | 22.15% |
| Dec 31, 2023 | 2.45M | 2.08M | 550.40% |
| Dec 31, 2022 | 377.00K | -123.00K | -24.60% |
| Dec 31, 2021 | 500.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Accuray | 401.95M |
| IRIDEX | 51.57M |
| Cytosorbents | 37.22M |
| Lifeward | 21.82M |
| Pulsenmore | 14.13M |
| InspireMD | 10.84M |
| Picard Medical | 6.30M |
| Sintx Technologies | 1.33M |
PAVM News
- 13 minutes ago - Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - PRNewsWire
- 1 day ago - Lucid Diagnostics Announces Publication of Landmark 12,000-Patient Real-World EsoGuard® Study - PRNewsWire
- 5 days ago - PAVmed to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 13, 2026 - PRNewsWire
- 6 days ago - Lucid Diagnostics to Hold Third Quarter 2026 Business Update Conference Call and Webcast on November 12, 2026 - PRNewsWire
- 12 days ago - Lucid Diagnostics begins receiving Medicare reimbursement for EsoGuard - TheFly
- 12 days ago - Lucid Diagnostics Begins Receiving Medicare Reimbursement for EsoGuard® and Closes $15 Million Financing - PRNewsWire
- 6 weeks ago - Lucid Diagnostics Advances Multiple EsoGuard® and EsoCheck® Payment, Billing and Coding Pathways - PRNewsWire
- 2 months ago - PAVmed price target raised to $57 from $56 at Ascendiant - TheFly